| Filed | Form | Description | |
|---|---|---|---|
| 12/3/25 | DEF 14A | DEF 14A | → |
| 3/3/25 | DEF 14C | DEF 14C | → |
| 2/21/25 | PRE 14C | PRE 14C | → |
| 1/22/25 | DEF 14C | DEF 14C | → |
| 1/10/25 | PRE 14C | PRE 14C | → |
| 12/6/24 | DEF 14A | DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 1/5/26 | 4 | 4 | → |
| 12/30/25 | 4 | OWNERSHIP DOCUMENT | → |
| 12/30/25 | 4 | OWNERSHIP DOCUMENT | → |
| 12/30/25 | 4 | OWNERSHIP DOCUMENT | → |
| 10/1/25 | 4 | 4 | → |
| 4/28/25 | 4 | OWNERSHIP DOCUMENT | → |
| ↓ | |||
S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).